Overview Dividends

(DDS) Dillard's - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US2540671011

Apparel, Accessories, Cosmetics, Home-Furnishings, Footwear

DDS EPS (Earnings per Share)

EPS Growth (3Y CAGR): -65.06%
EPS Trend (3Y Correlation): -62.3%

DDS Revenue

Revenue Growth (3Y CAGR): -0.86%
Revenue Trend (3Y Correlation): -20.3%

Description: DDS Dillard's November 06, 2025

Dillards, Inc. (NYSE: DDS) operates a network of department stores across the southeastern, southwestern and mid-Midwestern United States, selling apparel, accessories, cosmetics, home furnishings and other consumer goods both in-store and online via dillards.com, with additional clearance-center locations.

As of the most recent fiscal quarter, Dillards reported comparable-store sales growth of 2.8% year-over-year and an operating margin of roughly 7.5%, while maintaining a debt-to-EBITDA ratio near 2.2×, indicating modest leverage relative to peers.

The companys performance is closely tied to discretionary consumer spending trends, which are influenced by household income growth, inflationary pressure on apparel prices, and the competitive dynamics of e-commerce platforms that continue to erode foot traffic in brick-and-mortar retail.

For a deeper, data-driven look at how these factors translate into valuation risk and upside, you may find ValueRay’s analytical dashboards worth exploring.

DDS Stock Overview

Market Cap in USD	9,465m
Sub-Industry	Broadline Retail
IPO / Inception	1989-06-30

DDS Stock Ratings

Growth Rating	83.0%
Fundamental	75.1%
Dividend Rating	70.5%
Return 12m vs S&P 500	41.0%
Analyst Rating	2.0 of 5

DDS Dividends

Dividend Yield 12m	0.58%
Yield on Cost 5y	8.45%
Annual Growth 5y	156.57%
Payout Consistency	96.3%
Payout Ratio	2.9%

DDS Growth Ratios

Growth Correlation 3m	77.8%
Growth Correlation 12m	56.6%
Growth Correlation 5y	94%
CAGR 5y	32.58%
CAGR/Max DD 3y (Calmar Ratio)	0.78
CAGR/Mean DD 3y (Pain Ratio)	2.29
Sharpe Ratio 12m	0.75
Alpha	54.02
Beta	1.131
Volatility	39.60%
Current Volume	108.1k
Average Volume 20d	104.9k
Stop Loss	593.6 (-3.4%)
Signal	-0.20

Piotroski VR‑10 (Strict, 0-10) 7.5

Net Income (575.7m TTM) > 0 and > 6% of Revenue (6% = 395.1m TTM)

FCFTA 0.21 (>2.0%) and ΔFCFTA 6.40pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 24.50% (prev 24.79%; Δ -0.29pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.23 (>3.0%) and CFO 857.6m > Net Income 575.7m (YES >=105%, WARN >=100%)

Net Debt (-460.9m) to EBITDA (921.9m) ratio: -0.50 <= 3.0 (WARN <= 3.5)

Current Ratio 2.68 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (15.7m) change vs 12m ago -3.28% (target <= -2.0% for YES)

Gross Margin 39.37% (prev 41.20%; Δ -1.83pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 179.3% (prev 184.3%; Δ -5.05pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 97.57 (EBITDA TTM 921.9m / Interest Expense TTM 7.65m) >= 6 (WARN >= 3)

Altman Z'' 13.76

(A) 0.44 = (Total Current Assets 2.57b - Total Current Liabilities 958.7m) / Total Assets 3.68b

(B) 1.75 = Retained Earnings (Balance) 6.46b / Total Assets 3.68b

warn (B) unusual magnitude: 1.75 — check mapping/units

(D) 3.63 = Book Value of Equity 6.41b / Total Liabilities 1.77b

Total Rating: 13.76 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 75.12

1. Piotroski 7.50pt = 2.50

2. FCF Yield 8.75% = 4.38

3. FCF Margin 11.70% = 2.93

4. Debt/Equity 0.29 = 2.46

5. Debt/Ebitda -0.50 = 2.50

6. ROIC - WACC (= 14.27)% = 12.50

7. RoE 30.55% = 2.50

8. Rev. Trend -20.32% = -1.52

9. EPS Trend -62.25% = -3.11

What is the price of DDS shares?

As of November 06, 2025, the stock is trading at USD 614.69 with a total of 108,055 shares traded.
Over the past week, the price has changed by +0.62%, over one month by +0.01%, over three months by +32.76% and over the past year by +67.73%.

Is Dillard's a good stock to buy?

Partly, yes. Based on ValueRay´s Fundamental Analyses, Dillard's (NYSE:DDS) is currently (November 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 75.12 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of DDS is around 728.70 USD . This means that DDS is currently undervalued and has a potential upside of +18.55% (Margin of Safety).

Is DDS a buy, sell or hold?

Dillard's has received a consensus analysts rating of 2.00. Therefor, it is recommend to sell DDS.

Strong Buy: 0
Buy: 0
Hold: 1
Sell: 1
Strong Sell: 1

What are the forecasts/targets for the DDS price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	389.3	-36.7%
Analysts Target Price	389.3	-36.7%
ValueRay Target Price	820.8	33.5%

DDS Fundamental Data Overview October 27, 2025

Market Cap USD = 9.47b (9.47b USD * 1.0 USD.USD)
P/E Trailing = 16.7516
P/E Forward = 35.2113
P/S = 1.4372
P/B = 5.0753
P/EG = -1.28
Beta = 1.131
Revenue TTM = 6.59b USD
EBIT TTM = 746.3m USD
EBITDA TTM = 921.9m USD
Long Term Debt = 425.6m USD (from longTermDebt, last quarter)
Short Term Debt = 106.5m USD (from shortTermDebt, last quarter)
Debt = 551.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -460.9m USD (from netDebt column, last quarter)
Enterprise Value = 8.80b USD (9.47b + Debt 551.1m - CCE 1.21b)
Interest Coverage Ratio = 97.57 (Ebit TTM 746.3m / Interest Expense TTM 7.65m)
FCF Yield = 8.75% (FCF TTM 770.6m / Enterprise Value 8.80b)
FCF Margin = 11.70% (FCF TTM 770.6m / Revenue TTM 6.59b)
Net Margin = 8.74% (Net Income TTM 575.7m / Revenue TTM 6.59b)
Gross Margin = 39.37% ((Revenue TTM 6.59b - Cost of Revenue TTM 3.99b) / Revenue TTM)
Gross Margin QoQ = 34.64% (prev 44.56%)
Tobins Q-Ratio = 2.39 (Enterprise Value 8.80b / Total Assets 3.68b)
Interest Expense / Debt = 0.42% (Interest Expense 2.30m / Debt 551.1m)
Taxrate = 22.94% (21.7m / 94.6m)
NOPAT = 575.1m (EBIT 746.3m * (1 - 22.94%))
Current Ratio = 2.68 (Total Current Assets 2.57b / Total Current Liabilities 958.7m)
Debt / Equity = 0.29 (Debt 551.1m / totalStockholderEquity, last quarter 1.92b)
Debt / EBITDA = -0.50 (Net Debt -460.9m / EBITDA 921.9m)
Debt / FCF = -0.60 (Net Debt -460.9m / FCF TTM 770.6m)
Total Stockholder Equity = 1.88b (last 4 quarters mean from totalStockholderEquity)
RoA = 15.62% (Net Income 575.7m / Total Assets 3.68b)
RoE = 30.55% (Net Income TTM 575.7m / Total Stockholder Equity 1.88b)
RoCE = 32.31% (EBIT 746.3m / Capital Employed (Equity 1.88b + L.T.Debt 425.6m))
RoIC = 23.91% (NOPAT 575.1m / Invested Capital 2.41b)
WACC = 9.64% (E(9.47b)/V(10.02b) * Re(10.18%) + D(551.1m)/V(10.02b) * Rd(0.42%) * (1-Tc(0.23)))
Discount Rate = 10.18% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.09%
[DCF Debug] Terminal Value 69.03% ; FCFE base≈674.9m ; Y1≈613.3m ; Y5≈537.3m
Fair Price DCF = 591.4 (DCF Value 6.88b / Shares Outstanding 11.6m; 5y FCF grow -11.38% → 3.0% )
EPS Correlation: -62.25 | EPS CAGR: -65.06% | SUE: -4.0 | # QB: 0
Revenue Correlation: -20.32 | Revenue CAGR: -0.86% | SUE: 0.32 | # QB: 0

Additional Sources for DDS Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle